Stevanato Group S.p.A. reports developments in drug containment, drug delivery and diagnostic solutions for pharmaceutical, biotechnology and life sciences customers. The company’s updates center on financial results, revenue mix from high-value solutions, guidance, margin trends and demand across its Biopharmaceutical and Diagnostic Solutions and Engineering segments.
Recurring announcements also cover manufacturing capacity, customer demand for advanced containment and delivery products, investor conference participation and management commentary on operating performance. Its news flow connects healthcare packaging and delivery technologies with the commercial and clinical needs of drug developers, diagnostics companies and life sciences customers.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Stevanato Group (NYSE: STVN) announced it will release its Q1 2023 financial results on May 4, 2023, at 6:30 a.m. (ET). Following the release, a conference call will be held at 8:30 a.m. (ET) the same day, where management will discuss the results. Interested parties can pre-register for a conference passcode to gain immediate access or join via dial-in numbers provided for the location value="US"United States, location value="IT"Italy, and location value="GB"United Kingdom.
The company will also provide a webcast of the discussion live, which will be archived for three months on its Investor Relations website. Stevanato Group, founded in 1949, is renowned for its solutions in drug containment and delivery across the pharmaceutical and life sciences sectors.
Stevanato Group (NYSE: STVN) has partnered with Thermo Fisher Scientific to introduce an innovative on-body drug delivery system. This semi-reusable device allows for micro-precision dosing and bolus injections, enhancing patient adherence by facilitating at-home administration of pharmaceuticals. The collaboration promises an end-to-end solution, combining Stevanato's EZ-fill® cartridges with Thermo Fisher's fill-and-finish services. This partnership not only accelerates time-to-market but also supports sustainability through reduced waste. Both companies aim to improve patient access to critical medications while meeting market demands swiftly.
Stevanato Group S.p.A. (NYSE: STVN) has announced a strategic collaboration with Recipharm, aiming to develop pre-fillable syringes for use in Recipharm’s soft mist inhalers. This partnership leverages Stevanato's 70+ years of manufacturing experience. The Alba® syringes will integrate with Recipharm's Pre-Filled Syringe Inhaler (PFSITM) technology, enhancing drug delivery for sensitive products. The combined offering promises efficient respiratory delivery and improved containment solutions for biopharma companies. This collaboration underscores Stevanato's commitment to supporting drug development from clinical phases to market release.
Stevanato Group (NYSE: STVN), a global provider of drug containment and delivery solutions, announced its participation in the Virtual KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21 and March 22, 2023. The company will present on March 21 at 11:15 a.m. ET, with a live audio webcast available on their website. A replay will be accessible for approximately 90 days post-event. Founded in 1949, Stevanato Group offers an integrated portfolio of products and services across the drug life cycle, emphasizing research, technical innovation, and engineering excellence.
Summary not available.